These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 25457020)

  • 21. Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.
    Francini E; Yip S; Ahmed S; Li H; Ardolino L; Evan CP; Kaymakcalan M; Shaw GK; Kantoff PW; Taplin ME; Alimohamed NS; Joshua AM; Heng DYC; Sweeney CJ
    Clin Genitourin Cancer; 2018 Apr; 16(2):130-134. PubMed ID: 29331381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.
    Davies RS; Smith C; Lester JF
    Anticancer Res; 2016 Apr; 36(4):1799-803. PubMed ID: 27069162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reply to Kevin Lu's Letter to the Editor re: Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al. Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. Eur Urol 2015;68:147-53.
    Caffo O; Maines F; Veccia A
    Eur Urol; 2015 Dec; 68(6):e132-3. PubMed ID: 26320376
    [No Abstract]   [Full Text] [Related]  

  • 24. Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.
    Badrising SK; van der Noort V; Hamberg P; Coenen JL; Aarts MJ; van Oort IM; van den Eertwegh AJ; Los M; van den Berg HP; Gelderblom H; Vrijaldenhoven S; Kerver ED; van Voorthuizen T; de Jong IJ; Haanen JB; Bergman AM;
    Oncology; 2016; 91(5):267-273. PubMed ID: 27544669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Prior Use of an Androgen Receptor-Axis-Targeted (ARAT) Agent With or Without Subsequent Taxane Therapy on the Efficacy of Another ARAT Agent in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Miyake H; Hara T; Ozono S; Fujisawa M
    Clin Genitourin Cancer; 2017 Apr; 15(2):e217-e222. PubMed ID: 27522450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
    Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.
    Tassinari D; Cherubini C; Roudnas B; Tamburini E; Drudi F; Bianchi E; Fantini M; Montanari F; Sartori S
    Rev Recent Clin Trials; 2018; 13(3):226-237. PubMed ID: 29623850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide.
    Buttigliero C; Tucci M; Sonetto C; Vignani F; Di Stefano RF; Pisano C; Turco F; Lacidogna G; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
    Minerva Urol Nefrol; 2020 Dec; 72(6):737-745. PubMed ID: 32284527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of metastatic castration-resistant prostate cancer].
    Caffo O
    Recenti Prog Med; 2015 Jan; 106(1):35-9. PubMed ID: 25621779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
    de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
    Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer.
    Maines F; Caffo O; Veccia A; Trentin C; Tortora G; Galligioni E; Bria E
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):498-506. PubMed ID: 26318091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor-Axis-Targeted Agents in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
    Miyake H; Hara T; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
    Clin Genitourin Cancer; 2017 Aug; 15(4):e591-e597. PubMed ID: 28063845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzalutamide after docetaxel and abiraterone acetate treatment in prostate cancer: a pooled analysis of 10 case series.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Barni S
    Clin Genitourin Cancer; 2015 Jun; 13(3):193-8. PubMed ID: 25466676
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
    Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
    Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?
    Lebdai S; Basset V; Branchereau J; de La Taille A; Flamand V; Lebret T; Murez T; Neuzillet Y; Ploussard G; Audenet F
    World J Urol; 2016 May; 34(5):617-24. PubMed ID: 26373956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
    van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
    Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
    Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan.
    Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
    Clin Genitourin Cancer; 2018 Jun; 16(3):219-225. PubMed ID: 29274813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting.
    Oh WK; Cheng WY; Miao R; Vekeman F; Gauthier-Loiselle M; Duh MS; Drea E; Szatrowski TP
    Urol Oncol; 2018 Nov; 36(11):500.e1-500.e9. PubMed ID: 30201382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.
    Joshua AM; Shore ND; Saad F; Chi KN; Olsson CA; Emmenegger U; Scholz M; Berry W; Mukherjee SD; Winquist E; Haas NB; Foley MA; Dmuchowski C; Perabo F; Hirmand M; Hasabou N; Rathkopf D;
    Prostate; 2015 Jun; 75(8):836-44. PubMed ID: 25683285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.